WORLD PEPTIDEFOUNDATION

Peptides in 2TM · Amylin & Pramlintide

Episode 09 · 2:00 · English

Amylin & Pramlintide: the other meal-time signal

The amylin branch begins with the 1987 discovery papers, three amino-acid changes, the 2002 human trial and the 2005 U.S. Symlin approval. Explore a complementary meal-time signal, its clinical evidence and important safety context.

Download Episode 09 (MP4) ↓

English narration and optional captions. Caption timing is approximate. Translated subtitles are not yet available for this episode.

Published . Evidence cutoff: October 12, 2026.

Behind the film ↓Explore GLP-1 & beyond →Read the transcript ↓Find studies worldwide →Suggest a correction →

Behind the film: Amylin & Pramlintide references & context

Evidence cutoff: October 12, 2026. This film starts the amylin branch of the collection. Amylin and GLP-1 are distinct biological signals. WPF does not sell peptides or provide medical advice. Source verification is not independent human scientific review; no such review or institutional endorsement is claimed.

Discovery: credit more than one team

Two 1987 publications form the historical anchors. Westermark and colleagues investigated the peptide in pancreatic islet amyloid. Cooper and colleagues at Oxford purified and characterized a 37-amino-acid peptide from pancreatic extracts. These papers help trace identification of islet amyloid polypeptide, also called amylin. They should not be reduced to a sole-inventor story or treated as the discovery of every physiological effect at once.

The Oxford map identifies the publication’s institutional location. The later San Diego map supplies Amylin Pharmaceuticals’ development-location context. Neither identifies an exact discovery room or manufacturing plant. Clinical investigators, discovery researchers and commercial developers have different roles.

From natural peptide to engineered medicine

Pramlintide retains a 37-residue backbone but substitutes proline at three positions: A25P, S28P and S29P. These changes reduce aggregation propensity; they do not establish that aggregation is impossible under every condition. The film shows residues 22–33 in an original linear sequence diagram. It is not an atom-level structure, a receptor-binding pose or a molecular-dynamics simulation. The complete peptides also have features outside the displayed segment, including a disulfide bond and terminal amidation.

Primary source: FDA Office of Clinical Pharmacology and Biopharmaceutics review, 2005. Related early human investigation: pramlintide/AC137 study, PubMed 8778001.

Additional experimental/computational context: Effect of Proline Mutations on the Monomer Conformations of Amylin. Computational conformations are not clinical outcomes, and related engineered analogues are not automatically the marketed molecule.

Meal-related physiology

Amylin and insulin are co-secreted by pancreatic beta cells. Pramlintide’s documented effects include slower gastric emptying, a smaller post-meal glucagon rise and modulation of satiety. The organ scene separates stomach, liver-related glucose output and brain-mediated fullness; it does not show a literal particle traveling through these organs. Cell artwork is conceptual, not microscopy. The physiology is summarized from the Symlin label and FDA pharmacology materials above.

Human evidence: keep the time points straight

Whitehouse and colleagues reported a 52-week randomized, double-blind, placebo-controlled study of 480 people with type 1 diabetes, adding pramlintide to existing insulin treatment. At week 13, mean HbA1c reduction was 0.67 percentage points with pramlintide versus 0.16 with placebo. A statistically significant treatment difference persisted through week 52. The film’s displayed pair belongs to week 13, not week 52.

The trial reported weight differences and no increase in the overall severe-hypoglycemia event rate. That finding in a supervised study does not cancel the medicine’s boxed warning. Open-label follow-up differs from the randomized comparison. These results do not establish modern obesity-trial-scale weight loss or predict an individual response.

Whitehouse F and colleagues. Diabetes Care 25:724–730 (2002). PubMed 11919132 · DOI: 10.2337/diacare.25.4.724. The clinical publication’s first-author affiliation is Henry Ford Hospital, Detroit; that is distinct from the development-company location.

Approval, access and safety

Symlin received U.S. approval in 2005 as an adjunct for eligible adults with type 1 or type 2 diabetes using mealtime insulin whose glucose control remains inadequate despite optimal insulin therapy. It does not replace insulin. Nausea can occur, and combination with insulin carries a severe-hypoglycemia boxed warning, particularly in type 1 diabetes. The label includes restrictions concerning hypoglycemia unawareness and confirmed gastroparesis. These are selected points, not the complete prescribing information or instructions for self-treatment.

A U.S. milestone does not establish approval, reimbursement or present supply in other jurisdictions. The film does not claim current universal availability, give doses or insulin-adjustment instructions, or list purchasing sources. Longer-acting amylin medicines and amylin/GLP-1 combinations will be separate episodes, with their own evidence and regulatory dates.

Artwork and production provenance

  • Branding and closing: the established WPF insignia and complete spoken ending recur. The closing finishes before the final fade: “Peptides in 2. World Peptide Foundation. Every experience matters.”
  • Three new conceptual artworks: pancreatic secretory-cell environment, separate anatomical organs and an analytical laboratory inspired by NMR instrumentation. They are AI-created educational illustrations, not patient scans, authentic microscopy, actual Oxford/Amylin facilities or trial footage.
  • Maps: original location graphics based on Natural Earth public-domain geometry. City markers provide contextual locations, not precise facility addresses. Natural Earth terms.
  • Sequence diagram: original code-rendered residue comparison, with positions verified against source descriptions and the two sequences. Letters and positions are exact; visual spacing and colors serve readability.
  • Narration: established Tom synthetic British male voice; no scientist’s voice is cloned. Music is a new generated instrumental track, kept quiet under narration.
  • Font: Montserrat, SIL Open Font License; the license is included with the sources.

Download the English captions (VTT). Caption timing is approximate within measured narration segments.

Corrections or useful primary sources: admin@worldpeptidefoundation.org. Self-reported experiences remain distinct from clinical research and proof of effectiveness or safety.

Read the English transcript

Insulin is not the pancreas’s only meal-time signal. Amylin is released alongside it, helping coordinate what happens after we eat.

Two landmark papers in nineteen eighty-seven helped identify this peptide. Per Westermark and colleagues studied islet amyloid; Garth Cooper’s Oxford team purified and characterized its thirty-seven-amino-acid sequence.

Amylin helps slow stomach emptying, limit the rise in glucagon after a meal, and signal fullness through the brain. These actions complement insulin’s role in controlling blood glucose.

Native human amylin can aggregate. Scientists developed pramlintide by replacing three amino acids with proline, reducing that tendency while retaining amylin-like activity.

In one randomized trial in type one diabetes, haemoglobin A-one-C fell more with pramlintide than placebo. The treatment difference persisted through fifty-two weeks. This is glucose-control evidence, not a promise of dramatic weight loss.

Developed by Amylin Pharmaceuticals in San Diego, pramlintide received US approval as Symlin in two thousand five. It supplements mealtime insulin in eligible adults with diabetes; it does not replace insulin.

Nausea can occur. Combined with insulin, pramlintide can cause severe low blood sugar, especially in type one diabetes. Careful clinical supervision matters. Its history sets the stage for longer-acting amylin medicines.

Peptides in 2. World Peptide Foundation. Every experience matters.